Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,827,168 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,827,168 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,825,740 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,825,740 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,849,737 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,849,737 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,859,453 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,859,453 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,842,366 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,842,366 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2025 Filed May 6, 2025 01:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 1,748 | $51.56 | $90,130.73 |
DisclosureSEC source: 0001576280-25-000141 · wk-form4_1746493315.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,203,026 F1 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.43 to $51.76 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 6, 2025 01:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,445 | $50.91 | $175,394.60 |
DisclosureSEC source: 0001576280-25-000141 · wk-form4_1746493315.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,204,774 F1 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.405 to $51.34 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 6, 2025 01:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 44,691 | $49.53 | $2,213,710.59 |
DisclosureSEC source: 0001576280-25-000141 · wk-form4_1746493315.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,208,219 F1 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $50.06 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 6, 2025 01:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 38,477 | $48.71 | $1,874,299.32 |
DisclosureSEC source: 0001576280-25-000141 · wk-form4_1746493315.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,252,910 F1 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.185 to $49.16 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 6, 2025 01:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 18,069 | $47.67 | $861,275.15 |
DisclosureSEC source: 0001576280-25-000141 · wk-form4_1746493315.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,291,387 F1 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.18 to $48.175 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 23,998 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000106 · wk-form4_1743629170.xml · derivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,980 Underlying: Common Stock · 23,998 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 12,163 | $42.47 | $516,562.61 |
DisclosureSEC source: 0001576280-25-000106 · wk-form4_1743629170.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,309,456 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 23,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000106 · wk-form4_1743629170.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,321,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 4,814 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000106 · wk-form4_1743629170.xml · derivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,444 Underlying: Common Stock · 4,814 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests in four equal installments on the last day of each calendar quarter, March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 2,440 | $42.60 | $103,944.00 |
DisclosureSEC source: 0001576280-25-000106 · wk-form4_1743629170.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,297,621 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 4,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000106 · wk-form4_1743629170.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,300,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:21 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 68,769 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000086 · wk-form4_1742332910.xml · derivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:21 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 34,853 | $42.89 | $1,494,845.17 |
DisclosureSEC source: 0001576280-25-000086 · wk-form4_1742332910.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,295,247 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:21 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 68,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000086 · wk-form4_1742332910.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,330,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 116,010 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000082 · wk-form4_1741898778.xml · derivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,010 Underlying: Common Stock · 116,010 shares Expires not disclosed F3 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests with respect to 33% of the shares on January 1, 2026 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 19,258 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000082 · wk-form4_1741898778.xml · derivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,258 Underlying: Common Stock · 19,258 shares Expires not disclosed F1 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests in four equal installments on the last day of each calendar quarter, March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 94,555 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000006 · wk-form4_1735944848.xml · derivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,978 Underlying: Common Stock · 94,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This restricted stock unit award was granted on March 18, 2024 and vests with respect to 1/3 of the shares on January 1, 2025, and then quarterly for the remaining twenty-four months. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 43,309 | $30.55 | $1,323,089.95 |
DisclosureSEC source: 0001576280-25-000006 · wk-form4_1735944848.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,261,331 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 94,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000006 · wk-form4_1735944848.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,304,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 11,462 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000006 · wk-form4_1735944848.xml · derivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,462 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This restricted stock unit award was granted on March 18, 2024 and vests in four equal installments on the last day of each calendar quarter, March 31st, June 30th, September 30th, and December 31st, 2024. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 5,809 | $30.55 | $177,464.95 |
DisclosureSEC source: 0001576280-25-000006 · wk-form4_1735944848.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,210,085 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 11,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000006 · wk-form4_1735944848.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,215,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 11,461 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000230 · wk-form4_1727819981.xml · derivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,462 Underlying: Common Stock · 11,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This restricted stock unit award will vest in four equal installments on the last day of each calendar quarter, March 31st, June 30th, September 30th, and December 31st. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 5,809 | $22.94 | $133,258.46 |
DisclosureSEC source: 0001576280-24-000230 · wk-form4_1727819981.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,204,432 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 11,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000230 · wk-form4_1727819981.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,210,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:51 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 11,462 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000162 · wk-form4_1719953491.xml · derivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,923 Underlying: Common Stock · 11,462 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This restricted stock unit award will vest in four equal installments on the last day of each calendar quarter, March 31st, June 30th, September 30th, and December 31st. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:51 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 5,809 | $28.88 | $167,763.92 |
DisclosureSEC source: 0001576280-24-000162 · wk-form4_1719953491.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,198,780 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:51 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 11,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000162 · wk-form4_1719953491.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,204,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2024 Filed May 6, 2024 21:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionStock Option (Right to Buy) · Derivative | 283,830 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001576280-24-000098 · wk-form4_1715029398.xml · derivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,829 Underlying: Common Stock · 283,830 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| May 02, 2024 Filed May 6, 2024 21:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 283,830 | $4.18 | $1,186,409.40 |
DisclosureSEC source: 0001576280-24-000098 · wk-form4_1715029398.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,193,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 1, 2024 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 11,461 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000074 · wk-form4_1712006585.xml · derivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,385 Underlying: Common Stock · 11,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This restricted stock unit award will vest in four equal installments on the last day of each calendar quarter, 3/31/2024, 6/30/2024, 9/30/2024, and 12/31/2024. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 31, 2024 Filed Apr 1, 2024 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 4,509 | $20.63 | $93,020.67 |
DisclosureSEC source: 0001576280-24-000074 · wk-form4_1712006585.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,909,297 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 31, 2024 Filed Apr 1, 2024 21:23 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 11,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000074 · wk-form4_1712006585.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,913,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2024 Filed Mar 22, 2024 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 286,533 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000070 · wk-form4_1711142356.xml · derivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,533 Underlying: Common Stock · 286,533 shares Expires not disclosed F6 · derivative.exercise_date: This restricted stock unit award will vest with respect to 1/3 of the shares on January 1, 2025, and then quarterly for the remaining 24 months. F5 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 18, 2024 Filed Mar 22, 2024 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 45,846 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000070 · wk-form4_1711142356.xml · derivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,846 Underlying: Common Stock · 45,846 shares Expires not disclosed F4 · derivative.exercise_date: This restricted stock unit award will vest in four equal installments on the last day of each calendar quarter, 3/31/2024, 6/30/2024, 9/30/2024, and 12/31/2024. F5 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 18, 2024 Filed Mar 22, 2024 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherPerformance-Based Restricted Stock Units · Derivative | 1,130,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000070 · wk-form4_1711142356.xml · derivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,130,382 shares Expires 2027-05-26 F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · kind: This performance stock unit award that was granted on May 26, 2020 was cancelled and forfeited effective as of March 18, 2024. This was for good and valuable consideration, including continued employment with the Company. F2 · shares: This performance stock unit award that was granted on May 26, 2020 was cancelled and forfeited effective as of March 18, 2024. This was for good and valuable consideration, including continued employment with the Company. F3 · derivative.exercise_date: One-third of the granted performance-based restricted stock units vested and converted into shares of common stock based on the Issuer's achievement of the stock price milestone, as certified by the Issuer's compensation committee on January 2, 2021. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 4,250 | $26.40 | $112,188.10 |
DisclosureSEC source: 0001576280-23-000038 · wf-form4_167891824730198.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 24,250 F3 · price: Represents the weighted average price of shares purchased at prices that ranged from $26.00 to $26.58. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 4,250 | $26.40 | $112,188.10 |
DisclosureSEC source: 0001576280-23-000038 · wf-form4_167891824730198.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 24,250 F3 · price: Represents the weighted average price of shares purchased at prices that ranged from $26.00 to $26.58. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 8,500 | $26.40 | $224,376.20 |
DisclosureSEC source: 0001576280-23-000038 · wf-form4_167891824730198.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,902,345 F3 · price: Represents the weighted average price of shares purchased at prices that ranged from $26.00 to $26.58. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 13,906 | $26.04 | $362,101.12 |
DisclosureSEC source: 0001576280-23-000038 · wf-form4_167891824730198.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 20,000 F2 · price: Represents the weighted average price of shares purchased at prices that ranged from $25.965 to $26.20. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 6,094 | $24.78 | $151,006.27 |
DisclosureSEC source: 0001576280-23-000038 · wf-form4_167891824730198.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 6,094 F1 · price: Represents the weighted average price of shares purchased at prices that ranged from $24.65 to $25.00. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 13,906 | $26.04 | $362,101.12 |
DisclosureSEC source: 0001576280-23-000038 · wf-form4_167891824730198.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 20,000 F2 · price: Represents the weighted average price of shares purchased at prices that ranged from $25.965 to $26.20. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 6,094 | $24.78 | $151,006.27 |
DisclosureSEC source: 0001576280-23-000038 · wf-form4_167891824730198.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 6,094 F1 · price: Represents the weighted average price of shares purchased at prices that ranged from $24.65 to $25.00. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 27,813 | $26.04 | $724,228.27 |
DisclosureSEC source: 0001576280-23-000038 · wf-form4_167891824730198.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,893,845 F2 · price: Represents the weighted average price of shares purchased at prices that ranged from $25.965 to $26.20. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 12,187 | $24.78 | $301,987.77 |
DisclosureSEC source: 0001576280-23-000038 · wf-form4_167891824730198.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,866,032 F1 · price: Represents the weighted average price of shares purchased at prices that ranged from $24.65 to $25.00. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 100 | $98.00 | $9,800.00 |
DisclosureSEC source: 0001576280-21-000108 · wf-form4_163771240170350.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,853,845 Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 14,900 | $96.83 | $1,442,774.45 |
DisclosureSEC source: 0001576280-21-000108 · wf-form4_163771240170350.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,853,745 F5 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $96.50 to $97.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 5,000 | $95.50 | $477,500.00 |
DisclosureSEC source: 0001576280-21-000108 · wf-form4_163771240170350.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,838,845 Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 5,000 | $94.00 | $470,000.00 |
DisclosureSEC source: 0001576280-21-000108 · wf-form4_163771240170350.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,833,845 Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 23,467 | $93.05 | $2,183,637.20 |
DisclosureSEC source: 0001576280-21-000108 · wf-form4_163771240170350.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,828,845 F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $92.915 to $93.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.